Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J C Grutters

Showing results (21-30 of 71) with videos related to

Pageof 8
Sort By:
Clinical and Experimental Immunology|August 2, 2006
Toll-like receptor (TLR) 4 polymorphism Asp299Gly is not associated with disease course in Dutch sarcoidosis patientsM Veltkamp, J C Grutters, C H M van Moorsel, et al.
Sarcoidosis, Vasculitis, and Diffuse Lung Diseases : Official Journal of WASOG|March 1, 1997
Is the different T helper cell activity in sarcoidosis and extrinsic allergic alveolitis also reflected by the cellular bronchoalveolar lavage fluid profile?M Drent, J C Grutters, P G Mulder, et al.
Clinical and Experimental Immunology|April 8, 2015
Immunoglobulin A in serum: an old acquaintance as a new prognostic biomarker in idiopathic pulmonary fibrosisL Ten Klooster, C H M van Moorsel, J M Kwakkel-van Erp, et al.
Respiratory Medicine|December 13, 2017
Clubbing in patients with fibrotic interstitial lung diseasesM J G van Manen, L C Vermeer, C C Moor, et al.
Sarcoidosis, Vasculitis, and Diffuse Lung Diseases : Official Journal of WASOG|October 23, 2020
Safety of macitentan in sarcoidosis-associated pulmonary hypertension: a case-seriesH Mathijssen, M P Huitema, A L M Bakker, et al.
Sarcoidosis, Vasculitis, and Diffuse Lung Diseases : Official Journal of WASOG|February 16, 2011
CA 15-3 as an alternative marker for KL-6 in fibrotic lung diseasesA Kruit, W B M Gerritsen, N Pot, et al.
European Journal of Nuclear Medicine and Molecular Imaging|February 24, 2023
[89Zr]-immuno-PET prediction of response to rituximab treatment in patients with therapy refractory interstitial pneumonitis: a phase 2 trialH Adams, E M W van de Garde, D J Vugts, et al.
Respiratory Medicine|February 12, 2022
The detrimental effect of quantity of smoking on survival in progressive fibrosing ILDM G J P Platenburg, J J van der Vis, K M Kazemier, et al.
Lung|October 29, 2021
Humoral Immune Status in Relation to Outcomes in Patients with Idiopathic Pulmonary FibrosisT W Hoffman, C H M van Moorsel, K M Kazemier, et al.
Respiratory Medicine|March 1, 2022
Four-year survival rate in pulmonary sarcoidosis with extensive pulmonary hypertension screeningM P Huitema, H Mathijssen, A L M Bakker, et al.
Pageof 8

Showing results (21-30 of 71) with videos related to

Sort By:
Pageof 8
Clinical and Experimental Immunology|August 2, 2006
Toll-like receptor (TLR) 4 polymorphism Asp299Gly is not associated with disease course in Dutch sarcoidosis patientsM Veltkamp, J C Grutters, C H M van Moorsel, et al.
Sarcoidosis, Vasculitis, and Diffuse Lung Diseases : Official Journal of WASOG|March 1, 1997
Is the different T helper cell activity in sarcoidosis and extrinsic allergic alveolitis also reflected by the cellular bronchoalveolar lavage fluid profile?M Drent, J C Grutters, P G Mulder, et al.
Clinical and Experimental Immunology|April 8, 2015
Immunoglobulin A in serum: an old acquaintance as a new prognostic biomarker in idiopathic pulmonary fibrosisL Ten Klooster, C H M van Moorsel, J M Kwakkel-van Erp, et al.
Respiratory Medicine|December 13, 2017
Clubbing in patients with fibrotic interstitial lung diseasesM J G van Manen, L C Vermeer, C C Moor, et al.
Sarcoidosis, Vasculitis, and Diffuse Lung Diseases : Official Journal of WASOG|October 23, 2020
Safety of macitentan in sarcoidosis-associated pulmonary hypertension: a case-seriesH Mathijssen, M P Huitema, A L M Bakker, et al.
Sarcoidosis, Vasculitis, and Diffuse Lung Diseases : Official Journal of WASOG|February 16, 2011
CA 15-3 as an alternative marker for KL-6 in fibrotic lung diseasesA Kruit, W B M Gerritsen, N Pot, et al.
European Journal of Nuclear Medicine and Molecular Imaging|February 24, 2023
[89Zr]-immuno-PET prediction of response to rituximab treatment in patients with therapy refractory interstitial pneumonitis: a phase 2 trialH Adams, E M W van de Garde, D J Vugts, et al.
Respiratory Medicine|February 12, 2022
The detrimental effect of quantity of smoking on survival in progressive fibrosing ILDM G J P Platenburg, J J van der Vis, K M Kazemier, et al.
Lung|October 29, 2021
Humoral Immune Status in Relation to Outcomes in Patients with Idiopathic Pulmonary FibrosisT W Hoffman, C H M van Moorsel, K M Kazemier, et al.
Respiratory Medicine|March 1, 2022
Four-year survival rate in pulmonary sarcoidosis with extensive pulmonary hypertension screeningM P Huitema, H Mathijssen, A L M Bakker, et al.
Pageof 8